Core Viewpoint - The company is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its global development strategy, brand influence, and core competitiveness while optimizing its capital structure and broadening financing channels [1] Group 1 - The company aims to deepen its global development strategy and expand its overseas business layout [1] - The issuance of H-shares is intended to leverage the advantages of international capital markets [1] - The company is currently in discussions with relevant intermediaries regarding the specifics of the H-share listing [1] Group 2 - The H-share listing will not result in any changes to the actual control of the company [1]

证券代码：002340 证券简称：格林美 公告编号：2025-092 格林美股份有限公司 关于筹划发行 H 股股票并在香港联合交易所有限公司上市 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 格林美股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开第七届董事 会第六次会议、第七届监事会第五次会议，审议通过了《关于公司发行 H 股股票并 在香港联交所主板上市的议案》《关于公司发行 H 股股票并在香港联交所主板上市 方案的议案》等相关议案。现将有关情况公告如下： 将充分考虑现有股东的利益和境内外资本市场的情况，在股东会决议有效期内（即 经公司股东会审议通过之日起 24 个月或同意延长的其他期限）选择适当的时机和发 行窗口完成本次发行上市。 截至目前，公司正积极与相关中介机构就本次发行上市的相关工作进行商讨， 除本次董事会、监事会审议通过的相关议案外，其他关于本次发行上市的具体细节 尚未最终确定。 根据相关规定，公司本次发行上市尚需提交公司股东会审议，并需要取得中国 证券监督管理委员会、香港联交所、香港证券及期货事务监察委员会等相 ...

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange, aiming to enhance its global development strategy and strengthen its market position [2] Group 1 - The company aims to leverage international capital market resources and mechanisms to optimize its capital structure [2] - The move is expected to broaden financing channels and improve corporate governance and overall strength [2] - This initiative is part of the company's strategy to enhance brand influence and core competitiveness [2]